Phase 3 prospective, randomized, controlled, open-label, multicenter, crossover study of recombinant ADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura

June 25, 2023 | Marie Scully, MBE, M.D.; University College London Hospitals; NHS Foundation Trust; London, U.K.

RSS
123